Conferences

December 17, 2024

Discover how adding tafasitamab to lenalidomide + rituximab improves outcomes for relapsed/refractory follicular lymphoma patients.

December 10, 2024

Read research highlights from the ASH 2024 conference how certain lifestyle choices affect blood cancers.

December 07, 2024

Learn about new treatments and recommendations to current therapies from follicular lymphoma specialists speaking at the 2024 ASH conference.

December 02, 2024

The American Society of Hematology's annual conference is a significant event for the blood cancer community, including those involved in FL research.

November 15, 2024

New study shows IVIG replacement lowers infection risk in CLL and NHL patients, highlighting the need for better IgG testing and IgRT guidelines.

July 15, 2024

The bispecific antibody epcoritamab (Epkinly) was recently FDA-approved for the treatment of relapsed/refractory follicular lymphoma. Find out more!

July 09, 2024

First results of golcadomide, a new CELMoD, in monotherapy and with rituximab relapsed/refractory follicular lymphoma (non-Hodgkin Lymphoma) by Dr. Chavez.

May 27, 2024

The American Society of Clinical Oncology holds a yearly conference in June to allow researchers and doctors in the cancer community an opportunity to share…

May 06, 2024

Discover Evorpacept: A Next-Generation CD47 Checkpoint Inhibitor For Cancer Treatment with Enhanced Safety and Efficacy.

March 11, 2024

Dr. Nnawub shared research about how the type of insurance a patient has impacts their survival outcomes and the quality of care they receive.